Clinical trial

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

NCT06107673

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-09-30

PhasePHASE2

Study timeline

Study start (actual)2023-09-30Date precision: day

Registry last updated2025-12-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

DalpiciclibDRUG

Aromatase inhibitorDRUG

Docetaxel injectionDRUG · verified · RxNorm: docetaxel Injection

Epirubicin Hydrochloride InjectionDRUG

Cyclophosphamide injectionDRUG · verified · RxNorm: cyclophosphamide Injection

Sponsors & collaborators

Hebei Medical University Fourth Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06107673 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.